A true platform technology
iCRT-deter is an advanced controlled release carrier technology platform that offers powerful abuse deterrent features for highly potent or addictive compounds, including but not limited to opioids. It is highly flexible and can be applied to multiple routes of administration, including oral, sublingual and parenteral product forms.
It deters various routes of abuse, including solvent extraction and injection, via resistance to crushing, chewing, heating (the carrier has a very high melting point), and extraction in alcohol and common household solvents. The technology also offers a potential solution to alcohol induced dose-dumping.
iCRT-deter has been tested and proven across a range of compounds of varying solubility levels, and produced tablets are not bulky nor hard to swallow, benefiting the genuine patient.
The iCRT-deter carrier is based on FDA GRAS material, e.g. silica, and is on the inactive ingredients database. Development of iCRT-deter uses a green process, with a small carbon footprint, and is suitable for temperature-sensitive actives.
And we have demonstrated in-vitro bio-equivalence of our tablet formulation.
Easily formulated into and compatible with existing products to give immediate or extended release, iCRT-deter is a green process that also offers processing protection.
We’ve developed our platform with your patient in mind:
- Ease of use.
- Small, easy-to-swallow tablets.
- Tablets can be crushed for administration without releasing their APIs, yet still maintaining their controlled release properties.